Citation Tools

Download PDFPDF

800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

Download to a citation manager

Cite this article as:
Eigentler T, Heinzerling L, Krauss J, et al
800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors